



Date: February 12, 2019

Dr. Andreas Fouras, PhD
 CEO,
 4Dx Limited,
 468 St. Kilda Road,
 Melbourne, VIC 3004
 Australia

Melbourne, Australia

Re: Letter of support for MRFF grant

Dear Andreas,

It was with great interest that I learned about your thoughts on design and development of a novel human X Ray Velocimetry (XV) scanner with low dose or radiation-free solution for pediatric and neonatal subjects as a part of MRFF grant proposal. I strongly believe this solution will be game-changing, as we currently are limited on our ability to image changes in the lungs of preterm infants with bronchopulmonary dysplasia (BPD) with no diagnostic tool that allows us to quantify regional lung function, and follow responses to therapy.

As I understand, the Stage 1 of this grant plan involves design and development of 4Dx human scanner, while Stage 2 will involve clinical trial and validation. I'm happy to serve as an advisor on Stage1 and support and manage one of your clinical trial site at the University of Alabama at Birmingham in Stage 2. I'm excited about the opportunity to collaborate on this proposal and happy to provide my full support and expertise.

4DXV technology is an exciting and availability of state of art low-dose X Ray and radiation-free human scanner will provide an opportunity to address assessment of dynamic and regional pulmonary function changes with unique applications in neonatal and pediatric diseases. As such, it will cover the needs of all clinical segments of the pulmonary disease diagnosis as well as the evaluation of therapeutic efficacy. The current role (Stage 1) involving the advisory activity, will allow me to provide the clinical expertise on the early stage development of this novel human scanner with 4DXV capability. I look forward to the utilization of this novel human

scanner in image and regional lung function guided therapeutic intervention and procedures for treatment of pulmonary disorders.

I'm committed to support your initiative in Stage 2 of this activity that will allow us to expand this work into a clinical trial. My main research focus is on Bronchopulmonary Dysplasia (BPD) in preterm infants, a very heterogeneous condition with high mortality and morbidity, and we have very few tools to help guide therapy in infants with BPD. The use of the 4DXV imaging will enable us to evaluate and personalize therapy in infants with BPD, and will drive this field forward.

I look forward to working with continued development of 4DXV technology capable state-of-art human scanner.

Sincerely,



Namasivayam Ambalavanan MBBS, MD,
Co-Director, Division of Neonatology
Neonatal-Perinatal Medicine Fellowship Training Program Director
Director, Division of Neonatal Research
Professor, Department of Pediatrics
Email: nambalavanan@peds.uab.edu Tel: 205-934-4680